Novo Nordisk & The Challenge of Disease Management
Novo officials found Lilly's acquisition of PCS Health Systems Inc. hard to ignore. Of most immediate concern was the impact that the acquisition would have on the insulin marketplace, given its powerful presence in the US. How and to what extent should Novo respond?
You may also be interested in...
In a bid to protect its most valuable product, Lantus, Sanofi’s new diabetes division intends to provide holistic solutions in an effort to help patients better manage their disease. Will it work?
Less than a month after the LifeScan subsidiary of Johnson & Johnson said it was buying Inverness Medical Technologies, one of its main suppliers, it solidified another old friendship, this time with Novo Nordisk, the Danish maker of insulin and insulin delivery systems. The two companies announced a global alliance to develop and market a series of diabetes management devices--but withheld details. The two companies had previously teamed up in 1995.
The ex-GSK supply head Ian McCubbin will join the independent UK organization aimed at advancing cell and gene therapies, but notes issues with scale and manufacturing ahead.